

Antigen expression profile in circulating endothelial progenitor cells

Jean-Pierre Gagner* and Peter Shamamian*

*Department of Surgery, S.A. Localio Laboratory for Surgical Research, New York University School of Medicine, New York, NY 10016, USA.

New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.

Correspondence to P.S. e-mail: peter.shamamian@med.nyu.edu

The clinical applications of discoveries in angiogenesis and vasculogenesis research necessitate the development and validation of surrogate markers of tumour neovascularization and anti-angiogenic drug efficacy. Candidate biomarkers include circulating endothelial cells (CECs) shed by the tumour vasculature and circulating endothelial progenitors (CEPs) derived from the bone marrow, both measured by multiparametric flow cytometry. In their remarkable Review¹, Bertolini and colleagues define CEPs as expressing low levels of the pan-haematopoietic antigen CD45 (CD45^{dim}) (Figure 1). However, in the same article their flow cytometry approach consists of excluding all haematopoietic cells by sequential gating, thereby only selecting CD45-negative cells for further analyses (page 837 and Figure 2). Although the exact identity and function of CEPs is the subject of debate, these seemingly contradictory statements merit clarification. CEPs, defined as CD34⁺CD133⁺CD45^{dim}, CD34⁺VEGFR2⁺CD45^{dim} or CD34⁺CD133⁺VEGFR2⁺CD45^{dim} cells, have been reported to be present in the peripheral blood of cancer patients^{2,3}, cardiac patients⁴ and smokers⁵ as well as in umbilical cord blood². Nevertheless, the lack of haematopoietic antigen expression, such as CD45, has also been used to show the endothelial nature of CEPs and CECs^{6,7}. In addition, studies in murine models have documented the existence of bone-marrow-derived SCA1⁺FLK1⁺CD45⁺ and SCA1⁺TIE2⁺CD31⁺CD45⁺ endothelial precursor cell populations^{8,9}. These differences might reflect, in part, our limited understanding of the potential origin and steps of differentiation of CEPs toward the endothelial lineage in postnatal vasculogenesis^{10,11}. In light of the growing interest in vasculogenesis and anti-angiogenic therapy trials, we encourage the authors to clarify the issue.

1. Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. *Nature Rev. Cancer* **6**, 835–845 (2006).
2. Duda, D. G. *et al.* Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. *J. Clin. Oncol.* **24**, 1449–1453 (2006).
3. Fürstenberger, G. *et al.* Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. *Br. J. Cancer* **94**, 524–531 (2006).
4. Numaguchi, Y. *et al.* The impact of the capability of circulating progenitor cell to differentiate on myocardial salvage in patients with primary acute myocardial infarction. *Circulation* **114** (suppl. 1), I114–I119 (2006).
5. Kondo, T. *et al.* Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. *Arterioscler. Thromb. Vasc. Biol.* **24**, 1442–1447 (2004).
6. Blann, A. D. *et al.* Circulating endothelial cells. Biomarker of vascular disease. *Thromb. Haemost.* **93**, 228–235 (2005).
7. Ingram, D. A., Caplice, N. M. & Yoder, M. C. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. *Blood* **106**, 1525–1531 (2005).
8. Shaw, J. P., Basch, R. & Shamamian, P. Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. *Blood Cells Molec. Dis.* **32**, 168–175 (2004).
9. Qin, G. *et al.* Functional disruption of α 4 integrin mobilizes bone-marrow-derived endothelial progenitors and augments ischemic neovascularization. *J. Exp. Med.* **203**, 153–163 (2006).
10. Urbich, C. & Dimmeler, S. Endothelial progenitor cells. Characterization and role in vascular biology. *Circ. Res.* **95**, 343–353 (2004).

11. Porat, Y. *et al.* Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages. *Br. J. Haematol.* **135**, 703–714 (2006).